What Exactly Is Menopause Hormone Therapy?

During the menopausal transition, ovarian production of hormones—particularly estrogen—declines.

This hormonal change can contribute to symptoms including:

• hot flashes
• night sweats
• sleep disruption
• vaginal dryness
• pain or discomfort during intercourse
• some urinary symptoms

Menopause hormone therapy provides hormones to help compensate for this decline.

The terminology itself has changed.

You may still frequently hear hormone replacement therapy (HRT), but menopause hormone therapy (MHT) is increasingly used because treatment does not necessarily attempt to restore hormone concentrations to their premenopausal state.

And MHT is not one standardized medicine.

It is better understood as a family of treatments involving different hormones, formulations, doses and methods of delivery.

What Is Hormone Therapy Actually Used For?

The most established reason for systemic menopause hormone therapy is the treatment of bothersome vasomotor symptoms.

These include:

• hot flashes
• flushing
• night sweats

For some women, these symptoms are relatively mild.

For others, they can repeatedly interrupt sleep, affect concentration, interfere with work and significantly reduce quality of life.

Systemic estrogen is considered a highly effective treatment for these symptoms.

Hormone therapy may also help protect against the bone loss that accelerates around menopause.

Estrogen can also relieve symptoms involving vaginal dryness, burning, discomfort and painful intercourse.

However, when vaginal or urinary symptoms are the primary concern, low-dose local vaginal estrogen may be considered instead of whole-body systemic treatment.

Estrogen Alone or Estrogen Plus a Progestogen: Why Does the Uterus Matter?

This is one of the most important distinctions in menopause hormone therapy.

Estrogen stimulates the lining of the uterus, called the endometrium.

If systemic estrogen is used alone in a woman who still has her uterus, continued stimulation can cause the endometrium to become excessively thick and can increase the risk of endometrial cancer.

A progestogen is therefore generally added to provide endometrial protection.

This distinction is also important when interpreting studies about hormone therapy.

Estrogen-only therapy and combined estrogen-progestogen therapy should not automatically be treated as though they have identical risk profiles.

Tablet, Patch, Gel or Vaginal Treatment: Does the Route Matter?

Yes.

Hormone therapy can be delivered in several ways.

Systemic estrogen may be available as:

• oral tablets
• skin patches
• gels
• sprays
• certain vaginal rings

Low-dose vaginal estrogen may be available as creams, tablets, inserts or rings.

The route is not merely a matter of convenience.

Oral estrogen passes through the digestive system and liver before reaching the wider circulation.

Transdermal estrogen—delivered through the skin—largely avoids this first-pass liver metabolism.

This can influence effects on clotting factors, triglycerides and other metabolic processes.

That means the question should not always be:

“Is estrogen risky?”

It may need to become:

“Which estrogen, at what dose, through which route, for which woman?”

Who May Have a More Favourable Benefit-Risk Balance?

Age and timing are important parts of the discussion.

Mayo Clinic notes that for many healthy women who have bothersome symptoms and begin hormone therapy before age 60 or within 10 years of menopause, the benefits may outweigh the risks.

This does not create a universal cut-off where treatment suddenly becomes safe or unsafe.

Rather, it helps clinicians think about risk in context.

A healthy 52-year-old experiencing severe hot flashes soon after menopause is not necessarily in the same clinical situation as a woman beginning systemic hormone therapy for the first time decades after menopause.

Individual assessment remains essential.

What Are the Possible Risks?

This is where much of the confusion surrounding hormone therapy begins.

Depending on the individual and the treatment used, menopause hormone therapy may be associated with increased risks including:

• blood clots
• stroke
• heart disease
• breast cancer
• gallbladder disease
• endometrial cancer when estrogen is used without adequate endometrial protection in a woman with a uterus

But simply listing these risks can also be misleading.

The magnitude and relevance of risk depend on factors including:

• the woman's age
• time since menopause
• personal and family medical history
• whether estrogen is used alone or with a progestogen
• the particular hormone formulation
• the dose
• whether treatment is oral, transdermal or local
• how long treatment continues

This is why modern menopause care increasingly emphasizes individualized risk-benefit assessment.

Why Did Hormone Therapy Become So Controversial?

Much of the modern fear surrounding menopause hormone therapy can be traced to the Women's Health Initiative (WHI), a major set of clinical trials whose hormone-therapy findings attracted enormous attention beginning in 2002.

The trials raised concerns about outcomes including breast cancer, cardiovascular disease, stroke and blood clots.

Use of menopause hormone therapy subsequently declined sharply.

But the story did not end in 2002.

Longer follow-up and subsequent research have made the interpretation considerably more nuanced.

One particularly important distinction is that the WHI included separate trials of:

• estrogen plus a progestin in women with a uterus
• estrogen alone in women who had undergone hysterectomy

The outcomes were not identical.

Nor should findings from one particular hormone formulation automatically be assumed to apply identically to every estrogen, every progestogen, every route of delivery and every age group.

What About Breast Cancer?

For many women, this is the first concern that comes to mind when hormone therapy is mentioned.

It deserves careful discussion rather than a simple yes-or-no answer.

Breast-cancer risk is influenced by the type of hormone therapy and duration of treatment, among other factors.

Importantly, the WHI results differed between women receiving estrogen plus medroxyprogesterone acetate and women with previous hysterectomy receiving estrogen alone.

That means the statement:

“Hormone therapy causes breast cancer”

is too broad to accurately represent the evidence.

At the same time, the opposite claim—that hormone therapy has no meaningful breast-cancer considerations—would also be inappropriate.

A woman's baseline breast-cancer risk, the therapy being considered and its expected duration should form part of an individualized discussion with her healthcare professional.

What Does Menopause Have to Do With Blood Sugar and Metabolic Health?

This part of the story receives far less public attention than hot flashes.

The decline in estrogen around menopause is associated with broader metabolic changes.

These may include:

• greater central or abdominal fat accumulation
• changes in insulin sensitivity
• a more adverse lipid profile
• changes in cardiovascular risk

Importantly, these changes can occur even when the number on the weighing scale does not change dramatically.

For women already living with prediabetes or type 2 diabetes, menopause therefore arrives against an existing metabolic background.

This does not mean that menopause hormone therapy should be used as a diabetes treatment.

It should not.

But it does mean that glucose, weight distribution, blood pressure, cholesterol and overall cardiovascular health deserve attention during the menopausal transition.

If I Have Diabetes or Prediabetes, Does That Automatically Rule Out Hormone Therapy?

No—not automatically.

Having diabetes or prediabetes does not by itself answer whether menopause hormone therapy is appropriate.

The decision needs to consider the woman's wider cardiovascular and metabolic profile.

That may include:

• blood glucose control
• blood pressure
• cholesterol and triglycerides
• body weight and abdominal fat distribution
• smoking status
• history of cardiovascular disease
• history of stroke or blood clots
• other medicines being taken

The NCBI StatPearls review also discusses research examining hormone therapy and diabetes risk.

However, observational findings about diabetes incidence should not be interpreted as evidence that women should start menopause hormone therapy to prevent or treat diabetes.

The established clinical reason for systemic menopause hormone therapy remains primarily the management of appropriate menopause symptoms, with the overall benefit-risk balance considered individually.

Who Needs Particular Caution?

Systemic estrogen therapy may be inappropriate or require specialist assessment in women with certain medical histories.

Important considerations include:

• known, suspected or previous estrogen-sensitive breast cancer
• some other estrogen-sensitive cancers
• unexplained vaginal bleeding
• previous or active deep-vein thrombosis
• previous pulmonary embolism
• certain blood-clotting disorders
• previous stroke

Other health conditions may also alter the benefit-risk balance.

Importantly, contraindications and risks associated with systemic hormone therapy should not automatically be assumed to apply in exactly the same way to low-dose local vaginal estrogen, where systemic estrogen exposure is much lower.

This is another reason why discussing “HRT” as though it were one uniform treatment can create unnecessary confusion.

Does Hormone Therapy Mean Taking Hormones Indefinitely?

Not necessarily.

Modern treatment generally emphasizes using an appropriate dose that adequately controls symptoms and periodically reassessing whether treatment is still needed.

There is no single treatment duration appropriate for every woman.

Some women may need treatment for a relatively limited period.

Others may continue to experience troublesome symptoms for longer.

Mayo Clinic recommends regular review with a healthcare professional to make sure that the benefits of treatment continue to outweigh the risks.

Stopping hormone therapy can also lead to the return of vasomotor symptoms in some women.

So continuation and discontinuation should also be individualized rather than determined by an arbitrary date alone.

Menopause Hormone Therapy Myths Worth Avoiding

Myth: “Every woman should take hormones after menopause.”

Fact: No. Hormone therapy is a treatment option for particular symptoms and circumstances. Many women will not need systemic hormone therapy.

Myth: “HRT is dangerous for every woman.”

Fact: Risk varies according to age, timing, health history, hormone formulation, dose, route and whether estrogen is used alone or with a progestogen.

Myth: “All hormone therapy is the same.”

Fact: Oral estrogen, transdermal estrogen, estrogen-progestogen combinations and low-dose vaginal estrogen are not identical treatments.

Myth: “Estrogen and estrogen-plus-progestogen have exactly the same breast-cancer risk.”

Fact: They should not automatically be treated as equivalent. Major clinical trials have produced different findings for estrogen-only and combined therapy.

Myth: “If I have had a hysterectomy, I still always need progesterone.”

Fact: A progestogen is primarily added to systemic estrogen to protect the endometrium. Women who have had their uterus removed may not need it.

Myth: “A vaginal estrogen cream is the same as taking systemic HRT.”

Fact: Low-dose vaginal estrogen generally involves much lower systemic exposure and is primarily used for vaginal and urinary menopause symptoms.

Myth: “Hormone therapy should be taken to prevent diabetes.”

Fact: No. Although menopause, estrogen and metabolic health are interconnected and research has examined hormone therapy and diabetes risk, MHT should not be started simply as a diabetes-prevention treatment.

Myth: “Once hormone therapy is started, it never needs to be reviewed.”

Fact: Symptoms, health conditions and risk factors change. Treatment should be reviewed periodically with an appropriate healthcare professional.

Questions Worth Asking Your Doctor

• Are my symptoms likely to be related to perimenopause or menopause?
• How much are these symptoms affecting my sleep, work and everyday quality of life?
• Would systemic hormone therapy be appropriate for me?
• Would local vaginal estrogen be sufficient for my symptoms?
• Do I need estrogen alone or estrogen with a progestogen?
• Would an oral or transdermal treatment be more appropriate for my health profile?
• Do I have any personal risk factors for blood clots, stroke, cardiovascular disease or breast cancer?
• How does my family medical history affect the decision?
• If I have diabetes or prediabetes, does that change which treatment or route may be appropriate?
• Should my blood pressure, cholesterol, triglycerides or glucose control be reviewed?
• What benefits should I realistically expect from treatment?
• What side effects should I watch for?
• When should we review whether the treatment is working?
• What nonhormonal options are available if hormone therapy is not suitable for me?

Diafemme Perspective: Menopause Is Bigger Than the Hormone Debate

The hormone-therapy debate can easily become polarized.

Take hormones.

Never take hormones.

Neither is a particularly useful way to understand menopause.

A woman's menopause experience can involve sleep, mood, sexual health, bone health, body composition, metabolic health and cardiovascular risk—as well as hot flashes and menstrual changes.

Hormone therapy is one possible tool within that much larger picture.

For some women, it may substantially improve symptoms and quality of life.

For others, the risks may outweigh the likely benefits.

Some women may need only local treatment.

Others may prefer or require nonhormonal approaches.

Frequently Asked Questions

What is menopause hormone therapy?

Menopause hormone therapy uses hormones, particularly estrogen, to treat symptoms associated with declining ovarian hormone production during and after the menopausal transition. It was traditionally called hormone replacement therapy or HRT.

What symptoms can hormone therapy help?

Systemic estrogen can be highly effective for hot flashes and night sweats. Hormone therapy can also help some vaginal and urinary menopause symptoms and can help prevent bone loss.

Does every woman taking estrogen need progesterone?

No. Women who still have a uterus generally require a progestogen alongside systemic estrogen to protect the endometrium. Women who have undergone hysterectomy may not require it.

Is hormone therapy safe?

There is no universal answer. Benefits and risks depend on factors including age, time since menopause, personal health history, hormone formulation, dose, route and duration.

When may the benefits be more likely to outweigh the risks?

For many healthy women with bothersome symptoms who begin treatment before age 60 or within approximately 10 years of menopause, the benefit-risk balance may be favourable. Individual medical assessment is still required.

Does hormone therapy cause breast cancer?

The relationship is more complicated than a simple yes or no. Risk differs according to the type and duration of hormone therapy, and major trials have reported different findings for estrogen-only and combined estrogen-progestogen treatment.

Is a patch safer than a tablet?

The routes have different metabolic effects. Transdermal estrogen bypasses first-pass liver metabolism and may have advantages in some women, particularly where blood-clot or metabolic considerations are relevant. The most appropriate route should be individualized.

Is vaginal estrogen the same as systemic hormone therapy?

No. Low-dose vaginal estrogen is primarily used for vaginal and urinary menopause symptoms and results in much lower systemic estrogen exposure than whole-body therapy.

Can a woman with diabetes use menopause hormone therapy?

Diabetes does not automatically determine the answer. The decision should consider symptoms alongside the woman's broader cardiovascular, metabolic and medical risk profile.

Can hormone therapy prevent diabetes?

Hormone therapy should not be started simply to prevent or treat diabetes. Research has examined relationships between hormone therapy and diabetes risk, but this is not its primary clinical indication.

What if I cannot or do not want to take hormone therapy?

Nonhormonal approaches are available for menopause symptoms. Depending on the symptom, these can include lifestyle measures, cognitive behavioural therapy, vaginal moisturizers or lubricants and prescription nonhormonal medicines. Treatment should be matched to the symptoms that are causing difficulty.

Diafemme's Takeaway

Menopause hormone therapy is neither a universal solution nor something that every woman needs to fear.

It is an established treatment for bothersome menopause symptoms, particularly hot flashes and night sweats, and it can also help with vaginal symptoms and bone loss.

But precision matters.

Estrogen alone is not the same as estrogen plus a progestogen.

A tablet is not necessarily the same as a patch.

Low-dose vaginal estrogen is not the same as systemic treatment.

A woman shortly after menopause is not necessarily in the same risk situation as a woman starting treatment much later.

And menopause does not occur separately from the rest of a woman's health.

Changes in abdominal fat distribution, insulin sensitivity, lipids, bone and cardiovascular health can all become relevant during this transition.

For women with diabetes or prediabetes, that wider metabolic picture deserves particular attention.

So the most useful menopause conversation may not begin with:

“Should I take HRT?”

It may begin with:

“What is changing in my body, which symptoms are affecting my life, what are my individual health risks—and which treatment options make sense for me?”